| pubmed-article:6289963 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6289963 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:6289963 | lifeskim:mentions | umls-concept:C0027573 | lld:lifeskim |
| pubmed-article:6289963 | lifeskim:mentions | umls-concept:C0080194 | lld:lifeskim |
| pubmed-article:6289963 | lifeskim:mentions | umls-concept:C0007561 | lld:lifeskim |
| pubmed-article:6289963 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:6289963 | pubmed:dateCreated | 1982-12-16 | lld:pubmed |
| pubmed-article:6289963 | pubmed:abstractText | Ceftriaxone, a third generation cephalosporin, was used in a single intramuscular dose with oral probenecid to treat 124 men with infections due to non-penicillinase-producing Neisseria gonorrhoeae (non-PPNG) and 64 men with infections due to PPNG. Three different doses of ceftriaxone were used--125 mg, 62.5 mg, ad 32.5 mg, and 32.5. The cure rate for all PPNG infections with the different doses was 100%. The cure rate for the non-PPNG infections with ceftriaxone 125 mg was 100%; those for non-PPNG infections treated with ceftriaxone 62.5 mg and 32.5 mg were 96.2% and 97.3% respectively. The 160 strains of non-PPNG and 60 strains of PPNG isolated were all susceptible to ceftriaxone with minimum inhibitory concentrations of 0.008 microgram/ml. These results are compared with those using kanamycin 2 g. Ceftriaxone is a safe and effective treatment for PPNG and non-PPNG infections. | lld:pubmed |
| pubmed-article:6289963 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6289963 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6289963 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6289963 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6289963 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6289963 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6289963 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6289963 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6289963 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6289963 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6289963 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6289963 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6289963 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6289963 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6289963 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:6289963 | pubmed:issn | 0007-134X | lld:pubmed |
| pubmed-article:6289963 | pubmed:author | pubmed-author:ThirumoorthyT... | lld:pubmed |
| pubmed-article:6289963 | pubmed:author | pubmed-author:SngE HEH | lld:pubmed |
| pubmed-article:6289963 | pubmed:author | pubmed-author:RajanV SVS | lld:pubmed |
| pubmed-article:6289963 | pubmed:author | pubmed-author:GohC LCL | lld:pubmed |
| pubmed-article:6289963 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6289963 | pubmed:volume | 58 | lld:pubmed |
| pubmed-article:6289963 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6289963 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6289963 | pubmed:pagination | 314-6 | lld:pubmed |
| pubmed-article:6289963 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:6289963 | pubmed:meshHeading | pubmed-meshheading:6289963-... | lld:pubmed |
| pubmed-article:6289963 | pubmed:meshHeading | pubmed-meshheading:6289963-... | lld:pubmed |
| pubmed-article:6289963 | pubmed:meshHeading | pubmed-meshheading:6289963-... | lld:pubmed |
| pubmed-article:6289963 | pubmed:meshHeading | pubmed-meshheading:6289963-... | lld:pubmed |
| pubmed-article:6289963 | pubmed:meshHeading | pubmed-meshheading:6289963-... | lld:pubmed |
| pubmed-article:6289963 | pubmed:meshHeading | pubmed-meshheading:6289963-... | lld:pubmed |
| pubmed-article:6289963 | pubmed:meshHeading | pubmed-meshheading:6289963-... | lld:pubmed |
| pubmed-article:6289963 | pubmed:meshHeading | pubmed-meshheading:6289963-... | lld:pubmed |
| pubmed-article:6289963 | pubmed:meshHeading | pubmed-meshheading:6289963-... | lld:pubmed |
| pubmed-article:6289963 | pubmed:meshHeading | pubmed-meshheading:6289963-... | lld:pubmed |
| pubmed-article:6289963 | pubmed:meshHeading | pubmed-meshheading:6289963-... | lld:pubmed |
| pubmed-article:6289963 | pubmed:year | 1982 | lld:pubmed |
| pubmed-article:6289963 | pubmed:articleTitle | Ceftriaxone in the treatment of ordinary and penicillinase-producing strains of Neisseria gonorrhoeae. | lld:pubmed |
| pubmed-article:6289963 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6289963 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:6289963 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:6289963 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6289963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6289963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6289963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6289963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6289963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6289963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6289963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6289963 | lld:pubmed |
